PROGRAMME DCVMN 10TH ANNUAL GENERAL MEETING

14th-17th, September, 2009 Crown Plaza Park View Wuzhou Hotel, Beijing.

14:00	Conference registration and Hotel Check in	Crown Plaza Park View Wuzhou Hotel	
18:30	Welcome Cocktail and Dinner:	Hotel Garden	
	Welcome Address: Ms. Lifeng Wang, President, CN	BG	
Tuesday, 15 ^t	h September 2009 (Second day)		
	OPENING CEREMONY		
	Facilitator: Bing ZENG, Vice-President, CNBG		
8:30-9:00	Welcome & Opening Address	Akira Homma, DCVMN Chairman & Executive Director	
		Officer from Chinese MOH	
		Officer from Chinese SFDA	
	IMMUNIZATION VISION AND STRATEGY		
	Facilitator: Bing ZENG, Vice-president, CNBG		
9:00-10:30	1) WHO-UNICEF Global Immunization Vision and Strategy: Progress and Prospects for the Future	1) Thomas Cherian, Coordinator, IVE WHO	
	2) EPI Implementation in China	2) Xiaofeng LIANG, Director of Nationa Immunization Program Center, China CDC	
	3) Pandemic influenza H1N1 vaccine: prospects for availability in developing countries	3) Marie-Paule Kieny, Director, IVR WHO	
10:30-11:00	Refreshment Break (Group Photo)		
	LATEST DEVELOPMENT IN WHO GUIDELINE AND INITIATIVES		
	Facilitator: Xiaoming YANG: Director of CNBG WIBP		
11:00-12:30	1) WHO Prequalification	Carmen Rodriguez Hernandez, Scientist Prequalification Team, FCH/IVB/QSS WHO	
	2) WHO global batch release database: how to monitor all assured quality vaccines in the world	2) Lahouari Belgharbi, Scientist, IVB/QSS WHO	
	3) Development of WHO guidelines for lot release of vaccines	3) DianLiang LEI, Scientist, FCH/IVE QSS, WHO.	

12:30-13:30	Lunch		
	RESOURCE MEMBERS & FUNDING AGENCY OVERVIEWS AND INITIATIVES		
	Facilitator: Susan Loretan McKinney, Senior Technical Advisor for Immunization, USAID		
13:30-15:00	The trends in Global vaccine demand and supply, UNICEF vaccine procurement	1) Robert Matthews, Contracts Manager, Immunization Centre, UNICEF Supply Division	
	2) The Bill and Melinda Gates Foundation: Immunization and Vaccine development.	2) Julie Jacobson, Senior Program Officer, Global Health, Infectious Disease Development, Bill and Melinda Gates Foundation	
	3) GAVI alliance Accelerated Vaccine Introduction – progress report (AVI)	3) Jon Pearman, Head AVI, GAVI secretariat	
15:00-15:30	Refreshment Break		
15:30-17:00	VACCINE INNOVATION AND EVOLUTION		
	Facilitator: Yulin WANG, Deputy Director of CNBG LIBP		
	1) Improving access to vaccines in low and middle income countries. Contributions from the Netherlands Vaccine Institute (NVI)	1) Jan Hendriks, Account Manager, International Support, NVI	
	2) Malaria vaccine development of EMVI	2) Odile Leroy, Executive Director, European Malaria Vaccine Initiative, c/o Statens Serum Institute	
	3) Update on Cholera	3) Rodney Carbis, Head of Vaccine Development Department, IVI	
17:00	End of Session		
17:15	Departure from the Hotel for the Summer Palace		
19:00-21:00	Networking Dinner (Tingli Restaurant)		
21:00	Back to Hotel		
Wednesday, 16 th 2009 (Third day)			
	REGULATORY INITIATIVES	ATORY INITIATIVES	
	Facilitator: Baokui LIU, Director of Manufacture Coordination Department, CNBG		

8:30-10:00	1) Regulatory Strategy of Vaccine	1) HongZhang YIN, Director, Division of Biological products, SFDA.
	2) Vaccine Quality Control and Regulation in China	2) JunZhi WANG, Deputy Director, NICPBP
	3) Global vaccine market new trends: opportunities and challenges for emerging manufactures	3) Miloud Kaddar, Group leader, Financing, planning and procurement, EPI/IVB/FCH WHO
10:00-10:30	Refreshment Break	
10:30-12:30	PROJECT INTRODUCE	
	Facilitator: Limeng XU: Deputy Director of CNBG SIBP	
	1) PATH's Work in Vaccine Development	1) John Boslego, Director, Vaccine Development Global Program, PATH
	2) JE project/ public-private partnership	2) Mansour Yaich, Vaccine Development Advisor, PATH
	3) Project Optimize	3) Debra Kristensen, Senior Technical officer, PATH
	4) Innovation Bridge	4) Matt Davis, MD, University of Michigan, USA
12:30-13:30	Lunch	
	NEW TECHNOLOGIES	
	Facilitator: Ze CHEN, Assistant Director of CNBG	SIBP
13:30-16:00	1) Vaccine Presentation and Packaging Advisory Group and its relevance to the DCVMN	1) Selwyn Kahanovitz, CEO, Biovac
	2) Cost and Time Effective Production of Vaccine Antigens in Plants Using Transient Expression Vectors	2) Vidadi Yusibov, Executive Director, Fraunhofer USA Centre for Molecular Biotechnology
	3) The latest development in lyophilization and lyophilizer	3) Haibin Zhang, Vice President, Tofflon
	4) Towards an Integrated Vaccine Manufacturing Approach	4) Daria Donati, Marketing Manager, Vaccine Initiative, GE Healthcare Life Sciences
	5) Examining the impact of moving from vial to	5) Fiona Garin, Director, Strategic
	prefill	Marketing, Europe, BD Medical
	prefill 6) Achieving Robust and Consistent Vaccine Manufacturing Processes: Process Optimization and New Technology Developments	Marketing, Europe, BD Medical 6) Robert Shaw, Director, Strategic Marketing/ WW Training/ Vaccines and Emerging Biotech, Millipore Corp

VACCINE DEVELOPMENT AT DCVMN		
	Facilitator: Yuhua LI, Chief of Virus Vaccine Research Lab, CNBG CDIBP	
16:20-18:00	1) Comparison of Immunogenicity of TB Ag85a and ESAT-6 Delivered by Recombinant Modified Vaccinia Virus Ankara in Mice	1) Jueren LOU, Prof., China National Biotech Group
	2) Vaccine Innovation Strategy at Bio-Manguinhos/Fiocruz, Brazil	2) Akira Homma, CEO, BioManguinhos
	3) Prospects of Developing Countries Vaccine Manufactures' for Globally Used Vaccines	3) Suresh S.Jadhav, Exe. Director (QA), Serum Institute of India
	4) A New Inactivated JE Vaccine For Developing Countries	4) Mahima Datla, President, Biological E.
	5) The Development of Alternative Low-Cost Pneumococcal Vaccines at Instituto Butantan	5) CC Leite, Institute Butantan
	CLOSING REMARKS	
18:00	Summary & Conclusion	Akira Homma, DCVMN Chairman & Executive Director
	Farewell Dinner (OLJANIUDE)	
19:00	Farewell Dinner (QUANJUDE)	
	September (Fourth day) 2009_DCVMN AGM M	EMBERS ONLY
	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN	
	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun 1) New Developments/Innovations Vaccines at	m Institute of India Ltd.
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun	m Institute of India Ltd.
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun 1) New Developments/Innovations Vaccines at	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases – The Bharat Biotech	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serund 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases – The Bharat Biotech Response	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd.
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases – The Bharat Biotech Response 3) The Research of A H1N1 Influenza Vaccine	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd. 3) Zhaoxing SHI, SINOVAC 4) Abdulhussein Dalimi, Director General,
Thursday, 17 th	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serund 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases — The Bharat Biotech Response 3) The Research of A H1N1 Influenza Vaccine 4) Briefing on Razi institute and its activities	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd. 3) Zhaoxing SHI, SINOVAC 4) Abdulhussein Dalimi, Director General, Razi Vaccine & Serum Research Inst. 5) James Shih, Senior Manager, Xiamen
Thursday, 17 th 8:00-9:40	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serun 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases – The Bharat Biotech Response 3) The Research of A H1N1 Influenza Vaccine 4) Briefing on Razi institute and its activities 5) Clinic Trial of A New HEV Vaccine 1) DCVMN's Achievements between the year	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd. 3) Zhaoxing SHI, SINOVAC 4) Abdulhussein Dalimi, Director General, Razi Vaccine & Serum Research Inst. 5) James Shih, Senior Manager, Xiamen Innovax Biotech Co. Ltd.
Thursday, 17 th 8:00-9:40	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serund 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases — The Bharat Biotech Response 3) The Research of A H1N1 Influenza Vaccine 4) Briefing on Razi institute and its activities 5) Clinic Trial of A New HEV Vaccine 1) DCVMN's Achievements between the year 2008-2009	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd. 3) Zhaoxing SHI, SINOVAC 4) Abdulhussein Dalimi, Director General, Razi Vaccine & Serum Research Inst. 5) James Shih, Senior Manager, Xiamen Innovax Biotech Co. Ltd. 1) Dr. Akira Homma
Thursday, 17 th 8:00-9:40 9:40-10:20	September (Fourth day) 2009_DCVMN AGM M VACCINE DEVELOPMENT AT DCVMN Facilitator: Suresh Jahdav, Exe. Director(QA), Serund 1) New Developments/Innovations Vaccines at Bio Farma 2) Major Infectious Diseases — The Bharat Biotech Response 3) The Research of A H1N1 Influenza Vaccine 4) Briefing on Razi institute and its activities 5) Clinic Trial of A New HEV Vaccine 1) DCVMN's Achievements between the year 2008-2009 2) Annual Report	m Institute of India Ltd. 1) Isa Mansyur, President Director, PT Bio Farma 2) Sai D.Prasad, Bharat Biotech International Ltd. 3) Zhaoxing SHI, SINOVAC 4) Abdulhussein Dalimi, Director General, Razi Vaccine & Serum Research Inst. 5) James Shih, Senior Manager, Xiamen Innovax Biotech Co. Ltd. 1) Dr. Akira Homma

12:00-12:30	AGM Closing Remarks	Chairman of DCVMN
12:30	Lunch	
14:00-16:30	Tour to CNBG NVSI & Tiantan Bio	
16:30	See off	
GROUPACTI	VITY on 17 th September	
7:30-11:30	Various Group Activities around Beijing: Great Wall	
12:00	Lunch	'
14:00 -	Chosen from one of below: a. Tiananmen Square/ Forbidden City b. Tour to CNBG NVSI & Tiantan Bio	